

# Mymetics Corporation

## Overview

December 2016

# Important Notice

---



This document has been prepared by Mymetics Corporation ("Mymetics" or the "Company") for private circulation only. Mymetics is a public company listed on the OTC QB in the USA under MYMX whose European Executive Office is in Lausanne, Switzerland. This document should not be viewed as an offering circular, private placement memorandum or prospectus and does not constitute an offer, solicitation or invitation by or on behalf of Mymetics to any person to tender for, subscribe for, purchase or invest in any securities or any other investment. By accepting this document, the recipient agrees to keep this document confidential and not to reproduce it in whole or in part or distribute it outside of the firm to which it is provided without the written consent of Mymetics. At the request of Mymetics, the recipient must promptly return the document and all reproductions in whole or in part to Mymetics. The information and opinions contained in this document are for background purposes only and do not purport to be full or complete. It is not intended to provide the basis of any investment or other evaluation and is not and should not be construed as a recommendation or investment advice by Mymetics or any other person that any recipient of the document should make any investment. Mymetics has not independently verified the contents of the document. Accordingly, no representation, warranty or undertaking, express or implied, is made and no responsibility is accepted by Mymetics or any other party as to the accuracy or completeness in any respect of any information contained or statement made herein. All information in this document is subject to change without notice. The delivery of this document at any time does not imply that there has been no change since its date. This presentation includes forward-looking statements that relate to the Company's objectives, estimates and goals. Any statements that are not statements of historical fact should be considered forward-looking statements. The Company's business is subject to numerous risks and uncertainties, including the necessity to conduct further clinical trials and related studies, product testing and regulatory, approval, efficacy and safety. These and other risks and uncertainties could cause the company's actual results and developments to be materially different from those expressed or implied by any of these forward-looking Statements. Please refer to Mymetics' annual report as of December 31, 2015 on Form 10-K to the Securities and Exchange Commission for a full description of the Company's risks and operations. Any sales of the Company's securities pursuant to this confidential document are intended to be in compliance with Regulation S of the US Securities Act of 1933, as amended (the "Act"). It cannot therefore be made available to "US persons" within the meaning of rule 902(k) of the Act. No shares will be sold to US persons as defined above or to any person resident in the United States.

***Mymetics' vision is to become leading developer of the new generation virosome based vaccines for infectious diseases***

# Why Vaccines?

---

**Prevention better than Treatment:** Lower Cost of Health Care

**Currently only 26 Diseases are Prevented by Vaccines:** Many More to Address

**Significant Unmet Needs Remain:** 25% of worldwide annual deaths due to infectious disease (15M)<sup>1</sup>  
Major targets remain: RSV, CMV, HIV, HSV, ZIKA....

**Novel Vaccine Approaches Required**

**Vaccine Market to grow from \$33 Billion in 2014 to \$58 Billion in 2019 (CAGR 12%)**

**Priority Target for Big Pharma:** GSK, Merck, Pfizer, Sanofi, Pfizer (75%-80% of vaccine market)

**Growth Driven Mainly by Innovation:** Blockbuster premium priced vaccines in 2014 annual sales <sup>2</sup>

Pevnar 13 <sup>®</sup> :	\$4,297M
Gardasil <sup>®</sup> :	\$2,030M
Rotateq <sup>®</sup> & Rotarix <sup>®</sup> :	\$1,234M
Zostavax <sup>®</sup> :	\$ 765M

<sup>1</sup> Fauci, et al Emerging Infectious Diseases 11 (4); 2005

<sup>2</sup> EvaluatePharma; July 2015

- Vaccine specialists
- Differentiator: Virosome Platform Technology, applicable to broad range of high-value commercial vaccines
- Third Party Validation: Already strong License, Collaboration and Funding Agreements in place with major Pharma and Leading Foundations
- Strong Management Team and access to world class Scientific Advisors
- Strong IP protection with issued patents in all major territories
- Revenue generating, significant upside potential

---

Mymetics Corporation:	OTCQB MYMX – Venture Stage market Place and current in SEC reporting
Location / resources:	HQ in Lausanne, Switzerland and R&D in Leiden, the Netherlands, total of 10 FTEs
Core Competence:	World leading experts and IP in R&D and CMC for virosomes technology, integration and presentation of membrane proteins for innovative vaccine candidates against life threatening infectious diseases.
Pipeline:	Clinical stage: Intra-nasal Influenza, HIV and Malaria Pre-clinical: Chikungunya, RSV and HSV
Objective:	Build small / medium size innovative R&D virosome vaccine company with strong partnerships, Phase II – III clinical vaccine pipeline and have optionality for M&A or sale

## Recent Achievements

---

Jan. 2014 - **Out-license and collaboration deal for RSV vaccine** funded by Astellas.

\$ 5 million cash upfront, R&D service revenue, up to \$77 million in milestone payments and double digit royalties.

*Jan. 2016: Terminated for convenience by RSVC and collaboration will ended on July 25<sup>th</sup> 2016, Mymetics retaining all rights.*

Oct. 2014 - **Start of Gates Foundation \$1.8 million funded HIV vaccine study** at Texas Biomedical Research Inst.

Apr. 2016 – **Result:** 87% delay in persistent infection after 7 live virus vaginal challenges in NHPs. Analytics of mechanisms of action is ongoing.

Nov. 2014 - **Start of PATH-MVI funded study for transmission blocking malaria vaccine** candidate based on virosome technology and antigens from NIAID (LMIV).

Apr. 2016 – **Result:** High antibody titers and 95% to 100% inhibition of parasite transmission in high dose formulations.

Apr. 2015 – **Mymetics leading consortium awarded €8.4 million in grants** from EC (Horizon 2020) and Swiss innovation funds to develop thermostable and cold-chain independent virosome vaccines.



Sep. 2015 – Start of exploratory study of two new malaria antigens with Swiss Tropical & Public Health Institute and University of Zurich.

Jan. 2016 – **Start of discovery program on Chikungunya and ZIKA** virosome based vaccines



Dec. 2016 – **Start of Research Project with Sanofi Pasteur** on Influenza virosome vaccines

# Virosomes


- Virosomes are virus-like particles consisting of virus envelopes
- Virosomes lack the genetic material of the native virus: **virosomes are non-infectious**
- Retain the **receptor-binding** and **membrane fusion** properties of the virus
- Lipid membrane allows **optimal presentation and folding of antigens**



virus




virosome vaccine



virosome as carrier platform  
for vaccines



# Creating Virosomes



Starting Material:

Influenza virus as starting material

OR

Other enveloped virus (i.e. HSV, RSV, CMV, etc)

Reconstituted viral membrane = Virosome

# Advantages Virosome Platform

---

SAFETY:	No Genetic Material – Non Infectious
IMMUNOGENICITY:	Stay close to Nature by Reconstituting the Natural Viral Membrane Includes Natural Proteins of Virus Possibility to include Antigens and Adjuvants in Membrane Optimal Presentation to Immune System Strong Induction of Systemic (blood) & Mucosal Immunity
BROADLY APPLICABLE:	For any Enveloped Virus and as Antigen Carrier System
SCALABLE & COST:	Large Scale and GMP enabled and low COGS
ALREADY PROVEN:	Epaxal <sup>®</sup> (Hep A) & Inflexal <sup>®</sup> (flu) – JNJ; Invivac <sup>®</sup> - Abbott (flu)

Virosome Vaccines: The Safety of Killed Virus with the Immune Response of a Live Virus

# Product Pipeline

Product	Discovery	Pre-Clinical	Phase I	Phase II	Phase III	Virosome basis	Partners
RSV Prophylactic	Completed					RSV virus	On hold for now
HSV 1 + 2	Completed					HSV virus	On hold for now
Influenza Intra-nasal application Prophylactic	Completed					Influenza virus	Sanofi Pasteur
HIV-1 Prophylactic	Completed					Influenza virus + HIV antigens	BILL & MELINDA GATES foundation TEXAS BIOMEDICAL RESEARCH INSTITUTE
Malaria: Blood & Liver stage	Completed					Influenza virus + malaria antigens	Swiss TPH Swiss Tropical and Public Health Institute mvi PATH MALARIA VACCINE INITIATIVE
Transm. blocking	Completed						
New Virosome Vaccine Candidates Chikungunya, Zika							Own Program

## Summary of Pipeline results

---

### RSV vaccine:

- Strong RSV pre-clinical results: protection & absence of enhanced disease in cotton rats and mice.
- Publications: Vaccine, Jun. 2010.; PlosOne, May 2012; Vaccine, Feb. 2013

**Jan. 2014: License and Collaboration Agreement w. Astellas Pharma – ClearPath**

**Jan. 2016: Announced ending of Collaboration in July 2016 – Mymetics retaining all rights**

Intranasal Flu vaccine: Solvay / Abbott finished successfully a Phase I clinical trial with 100 people meeting / exceeding all EU (CHMP) criteria for injected influenza vaccines.

**Dec. 2016:** Start Research Project with Sanofi Pasteur

HIV vaccine: offering both blood and mucosal antibodies for optimal prevention of HIV-I mucosal transmission

- 100% protection in macaque monkeys against multiple heterologous virus challenges
- HIV Phase I proof-of-concept: strong safety and tolerance profile and presence of antibodies in mucosal secretions;
- Publications: Immunity, Feb. 2011; PlosOne, Feb. 2013.

**Oct. 2014:** Start of Bill & Melinda Gates Foundation Non Human Primates study with Texas Biomed.

**Apr. 2016 Result:** 87% delay in persistent infection after 7 live virus vaginal challenges in NHPs. Investigating mechanisms of action.

Malaria vaccine: Finished successfully Phase Ib on children in Tanzania (semi immune people). Strong safety and tolerance profile.

- Antibody presence up to 360 days & 50% lower attack rate.
- Publications: Plos One, 6: e22273, 2011

**Nov. 2014:** Start of PATH MVI funded study for transmission blocking virosome vaccine candidates with LMIV (NIAID)

**April 2016 Result:** high antibody titers and 95% to 100% inhibition of parasite transmission in high dose formulations.

## Financial Summary

---

- OTC QB: MYMX – current in SEC reporting and filings but not leveraged public listing until now
- 300 million shares outstanding, public float around 25%
- Recent stock price: 0.02 to 0.05 USD per share with very limited liquidity
- Capital Raised last 6 years: \$25 million in equity; \$35 million in convertible debt through private funding
- 55% of Company held by executives / board members
- Since September 2013 revenue generating and low cash burn

Revenue in 2015: US\$ 3.4 Million      EBITDA: US\$ 430k loss

Revenue in 2014: US\$ 2.7 Million      EBITDA: US\$ 730k loss

- Unique vaccine technology, know-how and IP: virosome as antigen carrier
- World leading virosome and membrane protein expertise and know-how
- Attractive and diverse pipeline with excellent results to date
- Out-licensing and collaboration agreement with leading Pharma for block buster RSV vaccine candidate
- Obtained non-dilutive funding from Gates Foundation, PATH MVI and EU Horizon 2020 for HIV and malaria vaccine development
- Revenue generating since Sep 2013
- Strong Management and Scientific Advisory Board
- Provides access to rapidly growing, high margin vaccine sector